Tokyo, Oct 23, 2007 (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. (TSE: 4519) announced today that “acute heart failure (including acute decompensation of chronic heart failure”) was supplementally approved on October 19, 2007 as an indication of Sigmart(R) 2mg Injection, Sigmart 12mg Injection, and Sigmart 48mg Injection (generic name: nicorandil; hereinafter referred to as “Sigmart(R) Injection”), which was already available on the market for the treatment of unstable angina pectoris.
